Prothena to Present Quality of Life Data on AL Amyloidosis at European Hematology Association 21st Congress
(Thomson Reuters ONE) -
DUBLIN, Ireland, May 19, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc
(Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the
discovery, development and commercialization of novel protein immunotherapies,
today announced that data from multiple quality of life studies in patients with
AL amyloidosis will be highlighted at The European Hematology Association (EHA)
21st Congress to be held June 9-12 in Copenhagen, Denmark.
"We look forward to sharing these qualitative and quantitative data that
advances the understanding of the impact of AL amyloidosis on patients' lives at
the upcoming EHA congress," commented Dale Schenk, PhD, President and Chief
Executive Officer of Prothena, "Our commitment to the amyloidosis community
involves not only research and development towards the goal of developing a new
therapy indicated for AL amyloidosis, but also a commitment to understanding the
impact of this devastating disease on patients' quality of life."
Data that highlights a variety of aspects of quality of life in AL amyloidosis,
including the relative burden of AL amyloidosis on health-related quality of
life for patients, the impact of treatment-related symptoms on treatment
compliance, impact on absenteeism, job productivity and loss, and validity of
psychometric properties of the SF-36v2® Health Survey, will be presented in the
following sessions:
(Abstract #P784) The Relative Burden of AL Amyloidosis on Health-related Quality
of Life
* Presenter: Spencer Guthrie, Head of Development Affairs, Prothena
Biosciences Inc.
* Session: Quality of life, palliative care, ethics and health economics 2
* Date and Time: Saturday, June 11, 2016 from 17:30 -19:00 CET
* Location: Poster Area (Hall H)
(Abstract #E1445) Treatment History, Tolerability and Impact on Health-Related
Quality of Life in AL Amyloidosis
* e-Poster presentation
(Abstract #E1458) The Impact of AL Amyloidosis on Absenteeism, Reduced
Productivity and Job Loss
* e-Poster presentation
(Abstract #E1441) Psychometric Validation of the SF-36V2® Health Survey in an AL
Amyloidosis Population
* e-Poster presentation
All e-Posters are available Friday, June 10, 9:30 to Saturday, June 11, 19:00
CET
About AL Amyloidosis
Systemic amyloidoses are a complex group of progressive diseases caused by
tissue deposition of misfolded proteins that result in progressive organ damage.
The most common type, AL amyloidosis or primary amyloidosis, involves a
hematological disorder caused by plasma cells that produce misfolded
immunoglobulin light chain resulting in deposits of abnormal AL protein
(amyloid) in the tissues and organs of individuals with this disease. There are
no approved treatments for AL amyloidosis, and none that directly target
potentially toxic forms of the AL protein. AL amyloidosis is a rare disorder and
it is estimated that about 30,000 to 45,000 patients in the U.S. and Europe
suffer from this disease. Both the causes and origins of AL amyloidosis remain
poorly understood. For more information on AL amyloidosis, please visit the
websites of the Amyloidosis Support Group and the Amyloidosis Foundation.
About Prothena
Prothena Corporation plc is a global, late-stage clinical biotechnology company
seeking to fundamentally change the course of progressive diseases with its
clinical pipeline of novel therapeutic antibodies. Fueled by its deep scientific
understanding built over decades of research in protein misfolding and cell
adhesion - the root causes of many serious or currently untreatable amyloid and
inflammatory diseases - Prothena has advanced several drug candidates into
clinical trials while pursuing discovery of additional novel therapies. Our
clinical pipeline of antibody-based product candidates targets a number of
potential indications including AL amyloidosis (NEOD001), Parkinson's disease
and other related synucleinopathies (PRX002) and inflammatory diseases including
psoriasis (PRX003).
Forward-looking Statements
This press release contains forward-looking statements. These statements relate
to, among other things, our goal to develop a new therapy specifically indicated
for AL amyloidosis. These statements are based on estimates, projections and
assumptions that may prove not to be accurate, and actual results could differ
materially from those anticipated due to known and unknown risks, uncertainties
and other factors, including but not limited to the risks, uncertainties and
other factors described in the "Risk Factors" sections of our Annual Report on
Form 10-K filed with the Securities and Exchange Commission (SEC) on February
25, 2016 and our subsequent Quarterly Reports on Form 10-Q filed with the SEC.
Prothena undertakes no obligation to update publicly any forward-looking
statements contained in this press release as a result of new information,
future events or changes in Prothena's expectations.
Contacts:
Investors: Tran Nguyen, CFO
650-837-8535, IR(at)prothena.com
Media: Ellen Rose, Head of Communications
650-922-2405, ellen.rose(at)prothena.com
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Prothena Corporation plc via GlobeNewswire
[HUG#2014095]
Unternehmensinformation / Kurzprofil:
Datum: 19.05.2016 - 22:05 Uhr
Sprache: Deutsch
News-ID 472530
Anzahl Zeichen: 6375
contact information:
Town:
DUBLIN
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 213 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Prothena to Present Quality of Life Data on AL Amyloidosis at European Hematology Association 21st Congress"
steht unter der journalistisch-redaktionellen Verantwortung von
Prothena Corporation plc (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
